Physician profile
John E Firestone
NPI 1386648830
$1,275.21
in general payments reported to CMS, 2019-2025
15 companies · $250 in 2025
The $250 reported for 2025 was more than what 80% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.49 · 2020: $15.04 · 2021: $26.86 · 2022: $210 · 2023: $313 · 2024: $448 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.90 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $609.89 | 2022-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $157.35 | 2021-2025 | Bexsero, Rotarix, Penmenvy |
| Corium, LLC | $106.44 | 2022-2024 | Azstarys |
| Pfizer INC. | $74.73 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $54.74 | 2023-2024 | Jornay Pm |
| Cranial Technologies, INC | $47.16 | 2024-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $46.32 | 2020-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Cipher Pharmaceuticals US LLC | $38.97 | 2025 | Natroba, Spinosad |
| Sanofi Pasteur INC. | $27.92 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $24.61 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $22.10 | 2024 | |
| Seqirus USA INC | $21.63 | 2024 | Flucelvax |
| Phadia US INC. | $17.50 | 2022 | |
| Organon LLC | $13.36 | 2025 | |
| Genentech USA, INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Firestone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.